121343-82-6

Basic information

• Product Name: Fmoc-L-glutamic acid
• Synonyms: N-Fmoc-L-glutamic Acid Fmoc-Glu-OH;(S)-2-((((9H-Fluoren-9-yl)Methoxy)carbonyl)aMino)pentanedioic acid;Fmoc-Glu;Fmoc-L-glutamic acid≥ 98% (HPLC);FMOC-GLU-OH;FMOC-GLUTAMIC ACID;FMOC-L-GLUTAMIC ACID;FMOC-L-GLU-OH
• CAS NO: 121343-82-6
• Molecular Formula: C₂₀H₁₉NO₆
• Molecular Weight: 369.37
• Product Categories: Amino Acids;Glutamic acid [Glu, E];Fmoc-Amino Acids and Derivatives;Amino Acids (N-Protected);Biochemistry;Fmoc-Amino Acids;Fmoc-Amino acid series
• Mol File: 121343-82-6.mol
• Article Data: 14

Chemical Properties

• Boiling Point: 635.8 °C at 760 mmHg
• Flash Point: 338.3 °C
• Appearance: /
• Density: 1.366 g/cm³
• Vapor Pressure: 4.89E-17mmHg at 25°C
• Refractive Index: 1.618
• Storage Temp.: Store at RT.
• PKA: 3.72±0.10(Predicted)
• Water Solubility: Slightly soluble in water.
• CAS DataBase Reference: Fmoc-L-glutamic acid(CAS DataBase Reference)
• NIST Chemistry Reference: Fmoc-L-glutamic acid(121343-82-6)
• EPA Substance Registry System: Fmoc-L-glutamic acid(121343-82-6)

Safety Data

• Safety Statements: 24/25
• Hazardous Substances Data: 121343-82-6(Hazardous Substances Data)

Usage

Chemical Properties

Solid

Uses

N-Fmoc-L-glutamic acid nonessential amino acid that is important to the mammalian central nervous system. It is also a neurotransmitter for cone photoreceptors in the human brain and is used as a treatment for patients who have liver disease accompanied by encephalopathy (a condition termed ?hepatic coma?).

InChI:InChI=1/C20H19NO6/c22-18(23)10-9-17(19(24)25)21-20(26)27-11-16-14-7-3-1-5-12(14)13-6-2-4-8-15(13)16/h1-8,16-17H,9-11H2,(H,21,26)(H,22,23)(H,24,25)/t17-/m0/s1

Upstream product

• 84793-07-7 Fmoc-Glu-OtBu 
• 56-86-0 L-glutamic acid 
• 82911-69-1 N-(9H-fluoren-2-ylmethoxycarbonyloxy)succinimide 
• 84418-43-9 9-fluorenylmethyl carbamate 
• 28920-43-6 (fluorenylmethoxy)carbonyl chloride 
• 1131148-55-4 1-[(9-fluorenylmethyloxycarbonyl)]benzotriazole 
• 1481642-14-1 (S)-4-((((9H-fluoren-9-yl)methoxy)carbonyl)amino)-5-methoxy-5-oxopentanoic acid 
• 71989-18-9 Fmoc-Glu(OtBu)-OH 

Downstream Products

• 129460-14-6 N-(9-fluorenylmethoxycarbonyl)glutamic acid di-tert-butyl ester 
• 1017606-16-4 H-Met-Pro-Pro-Glu-Val-Lys-Phe-Leu-NH₂ 
• 1217351-13-7 C₈₆H₁₂₆N₁₆O₃₈ 

Relevant articles and documents

SUPRAMOLECULAR GEL SUPPORTED ON OPEN-CELL POLYMER FOAM

The present invention relates to a polymer foam, said polymer foam comprising pores forming an open-cell polymer foam, said polymer foam comprising a supramolecular gel inside pores, and said polymer foam comprising at least one enzyme. The present invention relates to a supramolecular gel; its preparation and its applications, notably in chemical synthesis and kinetic resolution, in particular of organic compounds. The present invention also relates to flow chemistry.

Supported Catalytically Active Supramolecular Hydrogels for Continuous Flow Chemistry

Inspired by biology, one current goal in supramolecular chemistry is to control the emergence of new functionalities arising from the self-assembly of molecules. In particular, some peptides can self-assemble and generate exceptionally catalytically active fibrous networks able to underpin hydrogels. Unfortunately, the mechanical fragility of these materials is incompatible with process developments, relaying this exciting field to academic curiosity. Here, we show that this drawback can be circumvented by enzyme-assisted self-assembly of peptides initiated at the walls of a supporting porous material. We applied this strategy to grow an esterase-like catalytically active supramolecular hydrogel (CASH) in an open-cell polymer foam, filling the whole interior space. Our supported CASH material is highly efficient towards inactivated esters and enables the kinetic resolution of racemates. This hybrid material is robust enough to be used in continuous flow reactors, and is reusable and stable over months.

LIGANDS FOR ENHANCED IMAGING AND DRUG DELIVERY TO NEUROBLASTOMA CELLS

The present invention concerns aminobenzylguanidine derivative ligands specifically targeting neuroblastoma cells with an improved cellular uptake. The improved cellular uptake provides for the therapeutic and diagnostic use of the ligands in neuroblastoma-related diseases.